17 Mar 2015

Cyklokapron Tablets (Tranexamic acid) - United Kingdom

Cyklokapron Tablets

Generic Matches for Tranexamic acid (1)
Cyklokapron Injection

Last Updated on 17 Mar 2015 by EPG Health Media Staff

Suggest content to an epgonline.org editor - or let us know about a mistake you have spotted on this page

Cyklokapron Tablets Indication

Short-term use for haemorrhage or risk of haemorrhage in increased fibrinolysis or fibrinogenolysis. Local fibrinolysis as occurs in the following conditions:

- Prostatectomy and bladder surgery

- Menorrhagia

- Epistaxis

- Conisation of the cervix

- Traumatic hyphaema

- Hereditary angioneurotic oedema

- Management of dental extraction in haemophiliacs


Cyklokapron Tablets Generic Name

Tranexamic acid



Summary Product Characteristics (SPCs) Links
SPC - Cyklokapron 500 mg Film-coated Tablets (external site)

Related Learning Zones

CLL Knowledge Centre

CLL Knowledge Centre

The Chronic Lymphocytic Leukaemia (CLL) Knowledge Centre contains useful information arranged within three main sections: ‘Disease awareness’, ‘Events’ and ‘Resources’. Healthcare professionals will find information on pathophysiology, signs and symptoms of CLL, diagnosis, prognosis, treatment and management options, an upcoming events calendar and an external links listing.

Heart Failure

Heart Failure is a progressive chronic disorder that results in the inability of the heart to pump blood efficiently to the bodys tissues.

Chronic heart failure is an increasing public health problem; the growing prevalence in industrialised countries means that 1-2% of the adult population of these countries are now thought to have chronic heart failure.1-3 Estimates suggest that the prevalence in Europe, USA and Japan could increase by approximately 16.5% over the next ten years.4

Cyklokapron Tablets Marketing Information

Cyklokapron Tablets Generic Name
Tranexamic acid
Marketing Company
Meda Pharmaceuticals Ltd
Drug Type
Date of Issue, Marketing Authority 01/01/1983

Related Drugs - Haematology

Back to top